|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vokes EE and Stenson KM: Therapeutic
options for laryngeal cancer. N Engl J Med. 349:2087–2089. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mayne ST, Cartmel B, Kirsh V and Goodwin
WJ Jr: Alcohol and tobacco use prediagnosis and postdiagnosis, and
survival in a cohort of patients with early stage cancers of the
oral cavity, pharynx, and larynx. Cancer Epidemiol Biomarkers Prev.
18:3368–3374. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Freedman ND, Abnet CC, Leitzmann MF,
Hollenbeck AR and Schatzkin A: Prospective investigation of the
cigarette smoking-head and neck cancer association by sex. Cancer.
110:1593–1601. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sapkota A, Hsu CC, Zaridze D, Shangina O,
SzeszeniaDabrowska N, Mates D, Fabiánová E, Rudnai P, Janout V,
Holcatova I, et al: Dietary risk factors for squamous cell
carcinoma of the upper aerodigestive tract in central and eastern
Europe. Cancer Causes Control. 19:1161–1170. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Klein T and Bischoff R: Active
metalloproteases of the A Disintegrin and Metalloprotease (ADAM)
family: Biological function and structure. J Proteome Res.
10:17–33. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mochizuki S and Okada Y: ADAMs in cancer
cell proliferation and progression. Cancer Sci. 98:621–628. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Seals DF and Courtneidge SA: The ADAMs
family of metalloproteases: Multidomain proteins with multiple
functions. Genes Dev. 17:7–30. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu X, Lu D, Scully M and Kakkar V: ADAM
proteins-therapeutic potential in cancer. Curr Cancer Drug Targets.
8:720–732. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang W, Liu S, Liu K, Wang Y, Ji B, Zhang
X and Liu Y: A disintegrin and metalloprotease (ADAM)10 is highly
expressed in hepatocellular carcinoma and is associated with tumour
progression. J Int Med Res. 42:611–618. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ko SY, Lin SC, Wong YK, Liu CJ, Chang KW
and Liu TY: Increase of disintergin metalloprotease 10 (ADAM10)
expression in oral squamous cell carcinoma. Cancer Lett. 245:33–43.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee SB, Schramme A, Doberstein K, Dummer
R, AbdelBakky MS, Keller S, Altevogt P, Oh ST, Reichrath J, Oxmann
D, et al: ADAM10 is upregulated in melanoma metastasis compared
with primary melanoma. J Invest Dermatol. 130:763–773. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guo J, He L, Yuan P, Wang P, Lu Y, Tong F,
Wang Y, Yin Y, Tian J and Sun J: ADAM10 overexpression in human
non-small cell lung cancer correlates with cell migration and
invasion through the activation of the Notch1 signaling pathway.
Oncol Rep. 28:1709–1718. 2012.PubMed/NCBI
|
|
14
|
Lendeckel U, Kohl J, Arndt M, CarlMcGrath
S, Donat H and Röcken C: Increased expression of ADAM family
members in human breast cancer and breast cancer cell lines. J
Cancer Res Clin Oncol. 131:41–48. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gaida MM, Haag N, Günther F, Tschaharganeh
DF, Schirmacher P, Friess H, Giese NA, Schmidt J and Wente MN:
Expression of A disintegrin and metalloprotease 10 in pancreatic
carcinoma. Int J Mol Med. 26:281–288. 2010.PubMed/NCBI
|
|
16
|
Wang YY, Ye ZY, Li L, Zhao ZS, Shao QS and
Tao HQ: ADAM 10 is associated with gastric cancer progression and
prognosis of patients. J Surg Oncol. 103:116–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fu L, Liu N, Han Y, Xie C, Li Q and Wang
E: ADAM10 regulates proliferation, invasion, and chemoresistance of
bladder cancer cells. Tumour Biol. 35:9263–9268. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yue Y, Shao Y, Luo Q, Shi L and Wang Z:
Downregulation of ADAM10 expression inhibits metastasis and
invasiveness of human hepatocellular carcinoma HepG2 cells. Biomed
Res Int. 2013:4345612013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao H, Zhu J, Cui K, Xu X, O'Brien M,
Wong KK, Kesari S, Xia W and Wong ST: Bioluminescence imaging
reveals inhibition of tumor cell proliferation by Alzheimer's
amyloid beta protein. Cancer Cell Int. 9:152009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Endres K and Fahrenholz F: Upregulation of
the alpha-secretase ADAM10-risk or reason for hope? FEBS J.
277:1585–1596. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin T, Gu J, Zhang L, Davis JJ, Huang X,
Cabbini G, Ji L and Fang B: Enhancing adenovirus-mediated gene
transfer in vitro and in vivo by addition of protamine and
hydrocortisone. J Gene Med. 5:868–875. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
You Y, Yao H, You B, Li X, Ni H, Shi S,
Shan Y and Cao X: Clinical significance of HAX-1 expression in
laryngeal carcinoma. Auris Nasus Larynx. 42:299–304. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Edwards DR, Handsley MM and Pennington CJ:
The ADAM metalloproteinases. Mol Aspects Med. 29:258–289. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu K, Liao M, Liu B and Deng Z: ADAM-17
over-expression in gallbladder carcinoma correlates with poor
prognosis of patients. Med Oncol. 28:475–480. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zubel A, Flechtenmacher C, Edler L and
Alonso A: Expression of ADAM9 in CIN3 lesions and squamous cell
carcinomas of the cervix. Gynecol Oncol. 114:332–336. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu S, Zhang W, Liu K, Ji B and Wang G:
Silencing ADAM10 inhibits the in vitro and in vivo growth of
hepatocellular carcinoma cancer cells. Mol Med Rep. 11:597–602.
2015.PubMed/NCBI
|
|
28
|
Zhang W, Liu S, Liu K, Ji B, Wang Y and
Liu Y: Knockout of ADAM10 enhances sorafenib antitumor activity of
hepatocellular carcinoma in vitro and in vivo. Oncol Rep.
32:1913–1922. 2014.PubMed/NCBI
|
|
29
|
Maretzky T, Reiss K, Ludwig A, Buchholz J,
Scholz F, Proksch E, de Strooper B, Hartmann D and Saftig P: ADAM10
mediates E-cadherin shedding and regulates epithelial cell-cell
adhesion, migration, and beta-catenin translocation. Proc Natl Acad
Sci USA. 102:9182–9187. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Anders L, Mertins P, Lammich S, Murgia M,
Hartmann D, Saftig P, Haass C and Ullrich A: Furin-, ADAM 10-, and
gamma-secretase-mediated cleavage of a receptor tyrosine
phosphatase and regulation of beta-catenin's transcriptional
activity. Mol Cell Biol. 26:3917–3934. 2006. View Article : Google Scholar : PubMed/NCBI
|
